NCT01453101 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 54
- units
- Participants
- groups
- description
- Fludarabine monophosphate, melphalan, Bortezomib: •Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5. * Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2 * Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan.
- id
- BG000
- title
- Fludarabine, Melphalan, Bortezomib
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 18
- upper Limit
- 69
- value
- 56
- denoms
- counts
- group Id
- BG000
- value
- 54
- units
- Participants
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 19
- title
- Female
- measurements
- group Id
- BG000
- value
- 35
- title
- Male
- denoms
- counts
- group Id
- BG000
- value
- 54
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- denoms
- counts
- group Id
- BG000
- value
- 0
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Race and Ethnicity were not collected from any participant.
- title
- Race and Ethnicity Not Collected
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 54
- denoms
- counts
- group Id
- BG000
- value
- 54
- units
- Participants
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 54
- units
- Participants
- groups
- description
- Fludarabine monophosphate, melphalan, Bortezomib: •Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5. * Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2 * Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan.
- id
- BG000
- title
- Fludarabine, Melphalan, Bortezomib
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 18
- upper Limit
- 69
- value
- 56
- denoms
- counts
- group Id
- BG000
- value
- 54
- units
- Participants
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 19
- title
- Female
- measurements
- group Id
- BG000
- value
- 35
- title
- Male
- denoms
- counts
- group Id
- BG000
- value
- 54
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- denoms
- counts
- group Id
- BG000
- value
- 0
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Race and Ethnicity were not collected from any participant.
- title
- Race and Ethnicity Not Collected
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 54
- denoms
- counts
- group Id
- BG000
- value
- 54
- units
- Participants
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle